15h
The Brighterside of News on MSNNew CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...
The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...
Vanderbilt University Medical Center has been awarded up to $30 million by the Advanced Research Projects Agency for Health ...
Hosted on MSN2mon
Loosening chimeric antigen receptor's grip on T-regulatory cells improves function, researchers findA new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...
Researchers developed a cancer vaccine that uses tumor lysate to enhance immune recognition of solid tumors. The vaccine successfully targets melanoma, breast, lung and ovarian cancers in animal ...
3d
News Medical on MSNVanderbilt researchers aim to use AI to develop antibody therapies for any targetAn ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.
Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.
The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ...
This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...
The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results